Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has announced the results of a preclinical study of its lead compound, Telomir-1, conducted in an animal model of Werner Syndrome, a rare genetic disorder that causes premature aging. The study demonstrated that Telomir-1 effectively reset key biological aging markers, including DNA methylation, and restored healthy gene regulation. Notable findings included a significant increase in telomere length, a full reversal of muscle and body weight loss, up to a 50% reduction in oxidative stress markers, and 100% survival in treated animals compared to a 15% mortality rate in untreated controls. These results suggest that Telomir-1 may have potential as a therapeutic candidate for aging-related diseases. Telomir Pharmaceuticals plans to continue the development of Telomir-1, focusing on addressing mechanisms related to telomere dysfunction and epigenetic instability.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。